NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

BACKGROUND: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Enjoji, Munechika, Machida, Kazuyuki, Kohjima, Motoyuki, Kato, Masaki, Kotoh, Kazuhiro, Matsunaga, Kazuhisa, Nakashima, Manabu, Nakamuta, Makoto
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Short Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847569/
https://www.ncbi.nlm.nih.gov/pubmed/20222991
http://dx.doi.org/10.1186/1476-511X-9-29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847569/
https://www.ncbi.nlm.nih.gov/pubmed/20222991
http://dx.doi.org/10.1186/1476-511X-9-29

Ejemplares similares